| Wang, Yanxia |
NCT04863638: A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated |
|
|
| Active, not recruiting | 4 | 4400 | RoW | 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated, 2 doses of vaccine | China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd. | Covid19 | 12/21 | 03/24 | | |
NCT05386810: Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants |
|
|
| Completed | 3 | 1572 | RoW | Experimental vaccine, msIPV, IPV control vaccine, single-person sIPV control vaccine | Sinovac Biotech Co., Ltd | Poliomyelitis | 10/22 | 07/23 | | |
NCT05158777: Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old |
|
|
| Completed | 3 | 2480 | RoW | Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd., Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd | Shanghai Institute Of Biological Products | Varicella | 11/22 | 11/22 | | |
| Recruiting | 3 | 3975 | RoW | Sinovac PCV13, Prevnar® | Sinovac Life Sciences Co., Ltd. | Pneumococcal Infectious Disease | 03/25 | 04/26 | | |
| Not yet recruiting | 3 | 1200 | RoW | Recombinant Zoster Vaccine (CHO Cell) | MAXVAX Biotechnology Limited Liability Company | Herpes Zoster | 05/25 | 05/25 | | |
NCT05621655: Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers |
|
|
| Active, not recruiting | 2 | 1512 | RoW | Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine, High dose Recombinant Trivalent Subunit Rotavirus Vaccine, Placebo | MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention | Rotavirus Infections, Rotavirus Gastroenteritis | 04/23 | 04/24 | | |
NCT06113731: A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine |
|
|
| Recruiting | 2 | 980 | RoW | COVID-19 mRNA Vaccine (ZSVG-02-O), COVID-19 Vaccine (Vero Cell) ,Inactivated | CNBG-Virogin Biotech (Shanghai) Ltd. | SARS-CoV-2 Infection | 10/23 | 10/24 | | |
NCT05856084: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above |
|
|
| Active, not recruiting | 2 | 924 | RoW | Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control, Shingrix®, Placebo, Normal Saline for injection | MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention | Herpes Zoster | 02/24 | 03/26 | | |
NCT06080906: Phase II Clinical Trial of the Inactivated Rotavirus Vaccine |
|
|
| Recruiting | 2 | 600 | RoW | IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0, 28, Placebo on Day 0, 28, 56 | Institute of Medical Biology, Chinese Academy of Medical Sciences, Henan Center for Disease Control and Prevention | Rotavirus Infections, Diarrhea | 02/25 | 06/25 | | |
NCT05815264: Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above |
|
|
| Completed | 1 | 144 | RoW | 23-valent pneumococcal polysaccharide vaccine, pneumococcal vaccine polyvalent | Ab&b Biotechnology Co., Ltd.JS, Henan Center for Disease Control and Prevention | Pneumonia | 04/21 | 04/21 | | |
NCT05092386: Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine |
|
|
| Completed | 1 | 310 | RoW | Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13), Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13) | Sinovac Life Sciences Co., Ltd. | Pneumococcal Infections | 05/24 | 05/24 | | |
MKKCT-100-001, NCT05636436: Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above |
|
|
| Active, not recruiting | 1 | 132 | RoW | Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant, High dose adjuvant, Positive control, Shingrix®, Placebo, Saline for injection | MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention | Herpes Zoster | 12/24 | 12/24 | | |
| Recruiting | N/A | 600 | RoW | Acquired nurturing environment | Gansu Provincial Maternal and Child Health Care Hospital | Gestational Diabetes Mellitus in Pregnancy, Cognitive Impairment, Cohort Study | 11/25 | 11/25 | | |
| Yun, Li |
NCT06080906: Phase II Clinical Trial of the Inactivated Rotavirus Vaccine |
|
|
| Recruiting | 2 | 600 | RoW | IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0, 28, Placebo on Day 0, 28, 56 | Institute of Medical Biology, Chinese Academy of Medical Sciences, Henan Center for Disease Control and Prevention | Rotavirus Infections, Diarrhea | 02/25 | 06/25 | | |
